Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
Graybill WS, Vergote I, Pothuri B, Anttila M, O'Malley DM, Lorusso D, Haggerty AF, Fabbro M, Chan JK, Heitz F, Willmott LJ, Bruchim I, Zhuo Y, Estévez-García P, Monk BJ, Denys H, Knudsen A, Tinker AV, Sánchez LM, Provencher D, Barretina-Ginesta MP, Hartman J, Booth DV, González-Martín A.
Graybill WS, et al. Among authors: zhuo y.
J Comp Eff Res. 2024 Dec 6:e240133. doi: 10.57264/cer-2024-0133. Online ahead of print.
J Comp Eff Res. 2024.
PMID: 39641537
Free article.